Michaël Mellink - Aquilon Pharma

<img fetchpriority="high" decoding="async" width="616" height="260" src="https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored.png" alt="" title="" srcset="https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored.png 616w, https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored-480x203.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 616px, 100vw" class="wp-image-16" />

Partners
Projects
Press
Team
Jobs
Contact

News
About us
Technology
Portfolio
Pipeline
Investor relations

<img fetchpriority="high" decoding="async" width="616" height="260" src="https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored.png" alt="" title="" srcset="https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored.png 616w, https://aquilonpharma.com/wp-content/uploads/2023/05/logo_ap_colored-480x203.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 616px, 100vw" class="wp-image-16" />

a

External HR & Investment Advisor

Aquilon Pharma improves all aspects of drug development and commercialization thanks to its proprietary excipient technology.

News
About us
Technology
Portfolio
Pipeline
Investor relations

Partners
Projects
Press
Team
Jobs
Contact

Quai de la Boverie 59
4020 Liège
BELGIUM

info@aquilonpharma.com

+32 4 229 28 00

© 2007 – 2022 All Right Reserved

Terms of use
Cookie policy
Privacy policy

Website by DJM digital

×

News
About us
Technology
Portfolio
Pipeline
Investor relations

Partners
Projects
Press
Team
Jobs
Contact